Intratumoral administration of SZU101(another TLR7 agonist) triggers a systemic anti-tumor response and alters the TME by increasing CD4+ and CD8+ cells while reducing Treg cells in a murine breast tumor model (131). Here, TLR7 is linked to neoplasm.